Trial description
A Phase 2, Open-Label, 2-Arm, Response Rate Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer Who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)
Contact name
Dr Danish Mazhar
Trial start date
Wednesday, October 18, 2017
Trial end date
Tuesday, April 30, 2019
Trial tumour type
Show on Radiotherapy